Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Hong Kong · Delayed Price · Currency is HKD

2.200

-0.005 (-0.23%)

Oct 9, 2026, 9:42 AM HKT

Market Cap	484.62M -63.2%
Revenue (ttm)	67.26M -61.0%
Net Income	-37.13M
EPS	-0.19
Shares Out	193.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Open	2.200
Previous Close	2.205
Day's Range	2.200 - 2.265
52-Week Range	2.200 - 8.400
Beta	0.48
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. The company was founded in 2010 and i... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2010

Employees 68

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2496

Full Company Profile

Financial Performance

In 2025, Wuhan YZY Biopharma's revenue was 66.86 million, a decrease of -37.99% compared to the previous year's 107.81 million. Losses were -84.73 million, -13.18% less than in 2024.

Financial numbers in CNY Financial Statements